Arthritis Research & Therapy, 2019 Background This study investigates the association between exposure to urate-lowering drugs (ULDs) and progression and recovery from chronic kidney disease (CKD). Methods We identified 5860 incident gout patients at Chang Gung Memorial Hospital from 2012
Ting-Ting Chung +9 more
doaj +1 more source
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. [PDF]
, 2016 BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels.
Girardet, Jean-Luc +12 more
core +2 more sources
Diagnòstic i seguiment farmacoterapèutic de la hiperuricèmia i gota [PDF]
, 2017 Treballs d'Educació Farmacèutica als ciutadans. Unitat Docent d'Estades en Pràctiques Tutelades. Facultat de Farmàcia, Universitat de Barcelona. Curs: 2016-2017.
Barragán Muñoz, Àlex +4 more
core
Sintesis, penilaian biologi dan kajian dok sebatian auron ke atas enzim xantin oksidase [PDF]
, 2018 Perencatan aktiviti xantin oksidase (XO) merupakan satu pendekatan terapeutik yang berkesan dalam rawatan penyakit seperti gout dan hiperurikemia. Selain itu, penggunaan perencat XO juga dapat diluaskan kepada rawatan kecederaan contohnya reperfusi ...
Ang, Serene +4 more
core
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout [PDF]
, 2016 Alexandra Steinberg +5 more
openalex +1 more source
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol [PDF]
, 2021 Ajinkya Pawar +4 more
openalex +1 more source
Comparative effectiveness of allopurinol, febuxostat and benzbromarone on renal function in chronic kidney disease patients with hyperuricemia: a 13-year inception cohort study [PDF]
, 2017 Hsu‐Wen Chou +6 more
openalex +1 more source
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality. [PDF]
, 2019 Objective:The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed.
Pedersen, Brian +2 more
core
Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data‘ [PDF]
, 2020 Po‐Ke Hsu +2 more
openalex +1 more source